Please upgrade your browser

We built this website using the latest browser technologies to deliver the very best experience.

This makes the site run faster and easier to use. Unfortunately, your browser is out of date and will not support some of these technologies.

We recommend that you use a modern browser such as Google Chrome or Microsoft Edge to view this website.

Download ChromeDownload Microsoft Edge
Press release

Response to disciplinary notice

Oxford, U.K., 30 November 2021: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company”), the clinical AI company, has agreed settlement terms with the London Stock Exchange for a public censure and fine of £580,000, discounted to £406,000 for early settlement, for historical breaches of AIM Rules 13 and 31 in relation to the payment of certain IPO bonuses in 2018. 

November 30, 2021

Sensyne Health has fully cooperated with the London Stock Exchange during the period of its investigation over the past two years, and both acknowledges and reiterates its apology for its failure to properly understand and meet its AIM disclosure obligations during the first year of its listing as a public company, between November 2018 and October 2019. 

Since that period, Sensyne has taken significant steps to strengthen its governance to meet the standards required of a publicly listed company and is committed to upholding these standards. Over the past two years, the Board has overseen the successful implementation of recommendations from a Board effectiveness review conducted by A&O Consulting and recruited four new Independent Non- Executive Directors to strengthen the public market expertise of the Board. 

In parallel, the Company has reviewed its corporate governance structure and enhanced its procedures, resources and controls. 

The Board would like to thank Peel Hunt LLP, which continues to act as nominated adviser to the Company since admission to AIM in August 2018, for its guidance, advice and steadfast support. 

The Exchange Notice is available at: https://www.londonstockexchange.com/resources/raise-finance-resources?tab=aim

Press release

Response to disciplinary notice

November 30, 2021
Oxford, U.K., 30 November 2021: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company”), the clinical AI company, has agreed settlement terms with the London Stock Exchange for a public censure and fine of £580,000, discounted to £406,000 for early settlement, for historical breaches of AIM Rules 13 and 31 in relation to the payment of certain IPO bonuses in 2018. 

Sensyne Health has fully cooperated with the London Stock Exchange during the period of its investigation over the past two years, and both acknowledges and reiterates its apology for its failure to properly understand and meet its AIM disclosure obligations during the first year of its listing as a public company, between November 2018 and October 2019. 

Since that period, Sensyne has taken significant steps to strengthen its governance to meet the standards required of a publicly listed company and is committed to upholding these standards. Over the past two years, the Board has overseen the successful implementation of recommendations from a Board effectiveness review conducted by A&O Consulting and recruited four new Independent Non- Executive Directors to strengthen the public market expertise of the Board. 

In parallel, the Company has reviewed its corporate governance structure and enhanced its procedures, resources and controls. 

The Board would like to thank Peel Hunt LLP, which continues to act as nominated adviser to the Company since admission to AIM in August 2018, for its guidance, advice and steadfast support. 

The Exchange Notice is available at: https://www.londonstockexchange.com/resources/raise-finance-resources?tab=aim

Press release

Response to disciplinary notice

Response to disciplinary notice

November 30, 2021
Oxford, U.K., 30 November 2021: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company”), the clinical AI company, has agreed settlement terms with the London Stock Exchange for a public censure and fine of £580,000, discounted to £406,000 for early settlement, for historical breaches of AIM Rules 13 and 31 in relation to the payment of certain IPO bonuses in 2018. 

Sensyne Health has fully cooperated with the London Stock Exchange during the period of its investigation over the past two years, and both acknowledges and reiterates its apology for its failure to properly understand and meet its AIM disclosure obligations during the first year of its listing as a public company, between November 2018 and October 2019. 

Since that period, Sensyne has taken significant steps to strengthen its governance to meet the standards required of a publicly listed company and is committed to upholding these standards. Over the past two years, the Board has overseen the successful implementation of recommendations from a Board effectiveness review conducted by A&O Consulting and recruited four new Independent Non- Executive Directors to strengthen the public market expertise of the Board. 

In parallel, the Company has reviewed its corporate governance structure and enhanced its procedures, resources and controls. 

The Board would like to thank Peel Hunt LLP, which continues to act as nominated adviser to the Company since admission to AIM in August 2018, for its guidance, advice and steadfast support. 

The Exchange Notice is available at: https://www.londonstockexchange.com/resources/raise-finance-resources?tab=aim

Press release

Response to disciplinary notice

Response to disciplinary notice

Oxford, U.K., 30 November 2021: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company”), the clinical AI company, has agreed settlement terms with the London Stock Exchange for a public censure and fine of £580,000, discounted to £406,000 for early settlement, for historical breaches of AIM Rules 13 and 31 in relation to the payment of certain IPO bonuses in 2018. 

Sensyne Health has fully cooperated with the London Stock Exchange during the period of its investigation over the past two years, and both acknowledges and reiterates its apology for its failure to properly understand and meet its AIM disclosure obligations during the first year of its listing as a public company, between November 2018 and October 2019. 

Since that period, Sensyne has taken significant steps to strengthen its governance to meet the standards required of a publicly listed company and is committed to upholding these standards. Over the past two years, the Board has overseen the successful implementation of recommendations from a Board effectiveness review conducted by A&O Consulting and recruited four new Independent Non- Executive Directors to strengthen the public market expertise of the Board. 

In parallel, the Company has reviewed its corporate governance structure and enhanced its procedures, resources and controls. 

The Board would like to thank Peel Hunt LLP, which continues to act as nominated adviser to the Company since admission to AIM in August 2018, for its guidance, advice and steadfast support. 

The Exchange Notice is available at: https://www.londonstockexchange.com/resources/raise-finance-resources?tab=aim

Arrange to meet us
Press release

Response to disciplinary notice

November 30, 2021
Oxford, U.K., 30 November 2021: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company”), the clinical AI company, has agreed settlement terms with the London Stock Exchange for a public censure and fine of £580,000, discounted to £406,000 for early settlement, for historical breaches of AIM Rules 13 and 31 in relation to the payment of certain IPO bonuses in 2018. 

Sensyne Health has fully cooperated with the London Stock Exchange during the period of its investigation over the past two years, and both acknowledges and reiterates its apology for its failure to properly understand and meet its AIM disclosure obligations during the first year of its listing as a public company, between November 2018 and October 2019. 

Since that period, Sensyne has taken significant steps to strengthen its governance to meet the standards required of a publicly listed company and is committed to upholding these standards. Over the past two years, the Board has overseen the successful implementation of recommendations from a Board effectiveness review conducted by A&O Consulting and recruited four new Independent Non- Executive Directors to strengthen the public market expertise of the Board. 

In parallel, the Company has reviewed its corporate governance structure and enhanced its procedures, resources and controls. 

The Board would like to thank Peel Hunt LLP, which continues to act as nominated adviser to the Company since admission to AIM in August 2018, for its guidance, advice and steadfast support. 

The Exchange Notice is available at: https://www.londonstockexchange.com/resources/raise-finance-resources?tab=aim